Receive alerts
Market Cap:
$73.44 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 38


Orgenesis realigns resources with internal business transfers to support continued growth

It is transferring ownership of its Israeli cell process development business, Atvio Biotech, and its South Korean cell development unit, CureCell...

1 week, 2 days ago

Orgenesis Inc sees record fiscal 2Q revenue beat estimates

The company saw its revenue shoot up by 95% to $7.8 million, which easily beat the consensus estimate of $6.4 million...

1 week, 4 days ago

Orgenesis wins Orphan Drug designation for AIP cells for treating severe diabetes

CEO Vered Caplan says the designation will reduce time and costs of clinical development, helping the company get its AIP cell therapy to market faster...

on 06/17/2019

Orgenesis posts record fiscal 1Q profit, $7.3M in revenue as its contact manufacturing business booms

Orgenesis CEO Vered Caplan says the company’s financial performance is indicative of the 'rapid growth' in the cell and gene therapy market...

on 05/09/2019

Orgenesis to study liver cells as a suitable source for cell replacement therapy for insulin-dependent diabetics

Clinches approval to collect liver biopsies for future clinical use at Israel’s Rambam Medical Center...

on 04/30/2019

Orgenesis strikes deal with Columbia University to develop Cellular Vaccination product platform

Under the deal's terms, Orgenesis will receive a license on the technology developed at Columbia...

on 04/22/2019

Orgenesis strikes collaboration, license deal for exosome technologies with ExcellaBio

Orgenesis CEO Vered Caplan says exosomes have shown ‘significant promise’ as a novel alternative to whole cell therapies with ‘potentially superior safety’...

on 04/11/2019

Orgenesis strikes deal to develop 3D printing for cellular structures and tissues

Orgenesis will hold onto the exclusive rights to use and distribute the new cell printer systems...

on 04/04/2019

Orgenesis showcases publication of diabetes study in Stem Cell Research and Therapy Journal

The developer of advanced cell therapies points out that insulin-dependent diabetes is a disorder that could, in theory, be cured by functional pancreatic islets and the implantation of autologous insulin-producing cells...

on 04/03/2019

Orgenesis gains after announcing venture with TheraCell for cell and gene therapy development

TheraCell, operating in Greece, has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, chondral defects and chronic kidney injury...

on 03/28/2019

Orgenesis subsidiary MaSTherCell Global to build new facility in Belgium for cell and gene therapy manufacturing

The new 61,354 square foot production facility in Gosselies Biopark, in Belgium is expected to triple the company’s European capacity ...

on 03/25/2019

Orgenesis leads the charge at an exciting time for cell therapy

The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies ...

on 03/12/2019

Orgenesis stock climbs after it posts 139% expansion in gross profit for fiscal 2018 on revenue surge

The Maryland-based company is seeing steady revenue growth through an expansion of services, particularly in the area of CAR T-cell therapies ...

on 02/14/2019

Orgenesis unveils new offices, labs at Accessia Pharma in Belgium to boost its point-of-care cellular therapy platform

Orgenesis CEO Vered Caplan said the new laboratories in Belgium would “strengthen the roll-out” of the US company’s point-of-care strategy across Europe...

on 02/05/2019

Hemogenyx Pharma resetting the bar in blood cancers

"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland...

on 01/28/2019

Orgenesis kicks off US expansion of MaSTherCell Global subsidiary with Houston facility

It has executed a lease agreement to build a new 30,000 square feet manufacturing facility in Houston...

on 01/25/2019

Biotech CEOs gather in San Francisco to mull 2019 outlook

On the agenda at this year's Biotech Showcase is a panel discussion entitled “Cell and gene therapy: The financing surge” featuring Orgenesis CEO Vered Caplan...

on 01/04/2019